



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 446 699 A1

(12)

EUROPEAN PATENT APPLICATION

(21) Application number: 91102796.9

(22) Date of filing: 26.02.91

(51) Int. Cl.⁵: **C07K 5/06, C07C 271/10, C07C 271/20, C07C 271/24, C07C 275/20, C07C 275/26, C07C 279/04, C07C 279/16, C07C 281/02, C07C 281/06, C07C 281/16, //C07C335/06, C07C337/06, A61K31/155, A61K31/17, A61K31/27**

A request for correction of claims 1 and 9 has been filed pursuant to Rule 88 EPC. A decision on the request will be taken during the proceedings before the Examining Division (Guidelines for Examination in the EPO, A-V, 2.2).

(30) Priority: 26.02.90 US 485109
19.09.90 US 585349

(43) Date of publication of application:
18.09.91 Bulletin 91/38

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(71) Applicant: **MERRELL DOW
PHARMACEUTICALS INC.
2110 East Galbraith Road
Cincinnati Ohio 45215(US)**

(72) Inventor: Whitten, Jeffrey P.
9680 Tamarack Terrace
Cincinnati, Ohio 45241(US)
Inventor: Lambert, Laurie E.
7932 Kenneth Street
West Chester, Ohio 45069(US)
Inventor: McDonald, Ian A.
9382 Kentonsrun Court
Loveland, Ohio 45140(US)
Inventor: Doherty, Niall S.
22 Burr Road
Lyme, Connecticut 06371(US)

(74) Representative: **Vossius & Partner
Siebertstrasse 4 P.O. Box 86 07 67
W-8000 München 86(DE)**

(54) **Inhibitors of nitric oxide biosynthesis.**

(57) The present invention is directed to a new class of compound which are useful as inhibitors of the biosynthesis of nitric oxide.

EP 0 446 699 A1

The present invention is directed to a new class of arginine derivatives which are useful in inhibiting the biosynthesis of nitric oxide from L-arginine. A further aspect of the invention is directed to compositions containing these arginine derivatives which can be useful in the treatment of a number of disease states such as, for example, conditions associated with low blood pressure and to the treatment of inflammatory diseases and stroke.

It has recently been discovered that nitric oxide mediates a number of physiological processes. It serves as a signal transduction mechanism in the central nervous system, is intimately involved with the regulation of blood pressure, and is produced by activated inflammatory cells thereby playing a role in pathological inflammatory conditions.

Garthwaite et al. and Stevens reported that stimulation of the glutamate site of the NMDA receptor complex leads to the release of nitric oxide. The nitric oxide stimulates the guanylate cyclase present in the CNS which in turns leads to an increase in cyclic GMP levels. A great deal of attention has been focused upon these excitatory amino acid receptors because it is believed that they are associated with learning and development. It is also believed that over-stimulation of these receptors is associated with a number of disease states such as, for example, epilepsy, stroke, and neurodegenerative diseases such as senile dementia, etc. *Nature*, 336, pages 308-309 and 385-388 (November 1988).

Knowles et al. reported the mechanism by which the nitric oxide is formed. An enzymatic reaction occurs in which L-arginine is converted into nitric oxide and citrulline. Knowles et al. also reported that the presence of N-monomethyl-L-arginine inhibited this enzymatic transformation. *Proc. Natl. Acad. Sci. USA*, 86, pages 5159-5161 (July 1989).


Moncada et al. provided a review of the information which had been published to date regarding the physiological role of nitric oxide. Moncada et al. described the work of Knowles and Garthwaite regarding the role of nitric oxide in the CNS and postulated that nitric oxide is involved in seizures and other disease states associated with excessive excitatory neurotransmission. *Biochemical Pharmacology*, 38, No. 11, pages 1709-1715, (1989).

Moncada et al. reported that nitric oxide is associated with the regulation of blood pressure. These authors reported that an enzymatic pathway exists in the vasculature by which L-arginine is converted into nitric oxide. *Nature*, 333, pages 664-666 (1988). The nitric oxide relaxes the smooth muscles of the vasculature, producing dilation of these vessels which results in a lowering of blood pressure. Inhibition of nitric oxide synthesis by the administration of N-monomethyl-L-arginine produces a marked rise in blood pressure in test animals. *Proc. Natl. Acad. Sci. USA*, 86, pages 3375-3378 (1989).


Moncada et al. also reviewed earlier literature which reported that nitric oxide can be produced in large amounts by macrophages and polymorphonuclear leucocytes (PMN) and is associated with the effector functions of the cells. N-monomethyl-L-arginine inhibits the synthesis of nitric oxide by these cells.

Thus, it is the object of the present application to provide compounds capable of inhibiting the biosynthesis of nitric oxide. They would provide a new treatment for a number of disease states and could be utilized in the treatment of conditions associated with low blood pressure such as, for example, shock. They could also be used to treat conditions caused by over-activity of the NMDA receptor complex such as epilepsy, stroke, neurodegenerative diseases, etc. They could also be used to treat conditions associated with excessive production of nitric oxide by macrophages and polymorphonuclear leucocytes such as arthritis, cirrhosis, transplant rejections, etc.


This object has been achieved by the surprising finding that the biosynthesis of nitric oxide can be inhibited by the following class of arginine derivatives represented by the formulae Ia, Ib or Ic



Ia



Ib



Ic


in which:

- a) in Formula Ia, A is represented by $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$ or $-\text{CH}=\text{CR}-$; X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR_2 in which R_2 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl; and R is represented by an amino acid or OM, in which M is represented by H, C_{1-6} alkyl, benzyl, phenyl, pivoyl methyl ether, and the pharmaceutically acceptable salts thereof;
- b) in Formula Ib, R and X are as defined as above, Z is represented by O or NR_1 in which R_1 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl; and the pharmaceutically acceptable salts thereof and;
- c) in Formula Ic, W is represented by a substituent selected from the group consisting of $-\text{CH}_2-\text{NH}$, $-(\text{CH}_2)_2-\text{NH}$, $-\text{CH}_2-\text{NH}-\text{NH}$, $-\text{CH}_2-\text{O}-\text{NH}$, $-\text{NH}-\text{NH}$, and $-\text{O}-\text{NH}$; and R, Z, and X are as defined above; and the pharmaceutically acceptable salts thereof; with the following provisos:
- 1) that when W is $-\text{NH}-\text{NH}$ or $-\text{CH}_2-\text{NH}-\text{NH}$ then Z must be represented by O;
 - 2) when Z is represented by O and X is represented by NR_1 , then W must be $-\text{CH}_2-\text{NH}$ or $-(\text{CH}_2)_2-\text{NH}$ and;
 - 3) that when W is represented by CH_2-NH , Z is represented NH_2 , and X is NHR_2 , then R_2 is not represented by H.

The compounds encompassed by Formulae Ia-c inhibit the biosynthesis of nitric oxide. They prevent the bio-conversion of L-arginine into nitric oxide and citrulline. Thus these compounds will be useful in the treatment of a number of disease states in which excessive levels of nitric oxide are implicated.

As used in this application: the term,

- a) "cyano" refers to the following substituent: $-\text{CN}$;
- b) "cyclopropyl" refers to the following substituent:



- c) "2-propyne" refers to the following substituent: $-\text{CH}_2\text{C}\equiv\text{CH}$;
- d) "2,3-butadiene" refers to the following substituent: $-\text{CH}_2-\text{CH}=\text{C}=\text{CH}_2$;
- e) " C_{1-6} alkyl" refers to a straight chain, branched, or cyclic alkyl group containing up to 6 carbon atoms. Representative examples of suitable alkyl groups include, methyl, ethyl, propyl, isopropyl, n-butyl, t-butyl, pentyl, hexyl, cyclopropyl, and cyclopentyl;

f) "pivoyl methyl ether" refers to the following substituent: $-\text{CH}_2-\text{O}-\text{CO}-\text{C}(\text{CH}_3)_3$;

g) "amino acid" refers to one of the naturally occurring amino acids, and more preferably either aspartic acid or glutamic acid. The amino acids encompassed by the present invention are listed below in Table I. It is preferred that these amino acids be in their L-configuration. Their structures are disclosed in the well known text Lehninger's Biochemistry. The amine function of these amino acids is bonded to the carbonyl group adjacent to R in the compounds of Formula Ia-c.

TABLE I

<u>AMINO ACID</u>	<u>SYMBOL</u>
Alanine	Ala
Arginine	Arg
Asparagine	Asn
Aspartic acid	Asp
Cysteine	Cys
Glutamine	Gln
Glutamic acid	Glu
Glycine	Gly
Histidine	His
Isoleucine	Ile
Leucine	Leu
Lysine	Lys
Methionine	Met
Phenylalanine	Phe
Proline	Pro
Serine	Ser
Threonine	Thr
Tryptophan	Trp
Tyrosine	Tyr
Valine	Val

Since the compounds of Formula I are derivatives of the amino acid arginine, they can exist as acid addition salts, basic addition salts, as zwitterions, or as their free base. Thus the term "pharmaceutically acceptable salts" should be construed as encompassing pharmaceutically acceptable acid additions salts, pharmaceutically acceptable basic addition salts or the zwitterion form of the molecule.

The expression "pharmaceutically acceptable acid addition salts" is intended to apply to any non-toxic organic or inorganic acid addition salt of the base compounds represented by Formula Ia-c or any of its intermediates. Illustrative inorganic acids which form suitable salts include hydrochloric, hydrobromic, sulphuric, and phosphoric acid and acid metal salts such as sodium monohydrogen orthophosphate, and potassium hydrogen sulfate. Illustrative organic acids which form suitable salts include the mono-, di-, and

tricarboxylic acids. Illustrative of such acids are for example, acetic, glycolic, lactic, pyruvic, malonic, succinic, glutaric, fumaric, malic, tartaric, citric, ascorbic, maleic, hydroxymaleic, benzoic, hydroxy-benzoic, phenylacetic, cinnamic, salicylic, 2-phenoxy-benzoic, p-toluenesulfonic acid, and sulfonic acids such as methane sulfonic acid and 2-hydroxyethane sulfonic acid. Such salts can exist in either a hydrated or substantially anhydrous form.

The expression "pharmaceutically acceptable basic addition salts" is intended to apply to any non-toxic organic or inorganic basic addition salts of the compounds represented by Formula Ia-c or any of its intermediates. Illustrative bases which form suitable salts include alkali metal or alkaline-earth metal hydroxides such as sodium, potassium, calcium, magnesium, or barium hydroxides; ammonia, and aliphatic, alicyclic, or aromatic organic amines such as methylamine, dimethylamine, trimethylamine, and picoline.

All of the compounds of Formula Ia-c exist as optical isomers. Those compounds of Formula Ia-c in which X is represented by a butadiene will exist as stereoisomers as well. Those compounds of Formula Ia-c which are in the L-configuration are preferred due to their superior potency. However, any reference to the compounds of Formula Ia-c or to any of their intermediates should be construed as referring to either an optical isomer, an enantiomer, or to a racemic mixture. The specific optical isomers and enantiomers can be separated and recovered by techniques known in the art such as chromatography on chiral stationary phases or resolution via chiral salt formation and subsequent separation by selective crystallization. Alternatively utilization of a specific optical isomer or enantiomer as the starting material will produce the corresponding isomer or enantiomer as the final product.

Those compounds of Formula Ia, in which A is represented by an ethylene moiety, and all of the compounds of Formula Ib will exist as geometrical isomers. Any reference to the compounds of Formula Ia or Ib should be construed as encompassing either the cis or trans isomers.

Those compound of Formula Ib in which Z is represented by NR_2 , as well as those compounds of Formula Ic in which Z is NR_2 while W is $-\text{CH}_2\text{-NH}-$ or $-(\text{CH}_2)_2\text{-NH}-$ will exist as tautomers. The geminal nitrogen atoms will exist in a state of equilibrium in which they share a pair of electrons. Any reference to the compounds of Formula Ib or Ic should be construed as encompassing any of these tautomers.

Examples of compounds encompassed by Formula Ia-c include:

- 1) N^5 -(Hydrazino-iminomethyl)-2,5-diamino-3-pentenoic acid
- 2) N^5 -[Imino-(cyclopropylamino)methyl]-L-ornithine
- 3) N^5 -[Imino-(2-propyneamino)methyl]-L-ornithine
- 4) O-[Hydrazino-iminomethyl]-homoserine
- 5) N^5 -[Imino-(2-propyneamino)methyl]-2,5-diamino-3-pentenoic acid
- 6) N^5 -[Imino-(cyclopropylamino)methyl]-2,5-diamino-3-pentenoic acid
- 7) N^5 -(Hydrazino-carbonyl)-L-ornithine
- 8) O-[Hydrazino-carbonyl]-homoserine
- 9) N^5 -(Hydrazino-carbonyl)-2,5-diamino-3-pentenoic acid
- 10) N^5 -(Hydrazino-iminomethyl)-2,5-diamino-3-pentenyl-N-L-aspartate
- 11) N^5 -(Hydrazino-iminomethyl)-2,5-diamino-3-pentenyl-N-L-glutamate
- 12) N^5 -[Imino-(cyclopropylamino)methyl]-L-ornithinyl-N-L-glutamate
- 13) N^5 -[Imino-(cyclopropylamino)methyl]-L-ornithinyl-N-L-aspartate
- 14) N^5 -[Imino-(2-propyneamino)methyl]-L-ornithinyl-N-L-glutamate
- 15) N^5 -[Imino-(2-propyneamino)methyl]-L-ornithinyl-N-L-aspartate
- 16) N^5 -[Imino-(2-propyneamino)methyl]-2,5-diamino-3-pentenyl-N-L-aspartate
- 17) N^5 -[Imino-(2-propyneamino)methyl]-2,5-diamino-3-pentenyl-N-L-glutamate
- 18) N^5 -[Imino-(cyclopropylamino)methyl]-L-ornithinate methyl ester
- 19) N^5 -[Imino-(2-propyneamino)methyl]-2,5-diamino-3-pentenoate methyl ester
- 20) O-[Hydrazino-carbonyl]-5-hydroxynorvaline
- 21) O-(Cyclopropylamine-carbonyl)-6-hydroxynorleucine
- 22) O-[Hydrazino-carbonyl]-2-amino-5-hydroxy-3-pentenoic acid
- 23) N^5 -[Hydrazino-methyliminomethyl]-L-ornithine, flavinate
- 24) N^5 -[Hydrazino-iminomethyl]-L-canaline, flavinate
- 25) N^6 -[Hydrazino-iminomethyl]-L-lysine, flavinate
- 26) N^7 -[Hydrazino-iminomethyl]-2-amino-5-aminoxy-pentenoic acid, flavinate
- 27) N^6 -[Hydrazino-carbonyl]-lysine
- 28) N^5 -(Cyclopropylamino-carbonyl)-2-amino-4-hydrazino-butanoic acid
- 29) N^7 -(Cyclopropylamino-carbonyl)-2-amino-5-hydrazino-pentanoic acid

The substituent which is present at the X position can affect the relative activity of the compounds. Those compounds in which X is a bulky substituent such as 2-propyne, cyclopropyl, or 2,3-butadiene show


superior activity for inhibiting the production of nitric oxide within the CNS.

The compounds of Formula Ia-c can be made using techniques well known in the art. Those compounds which can be described by Formula Ia can be made using the synthesis outlined below in Reaction Scheme I:

REACTION SCHEME I


STEP A

DISPLACEMENT




STEP B

AMIDATION




STEP C

DEPROTECTION



STEP D

OPTIONAL FUNCTIONALIZATION


$$Y = Cl, OCCl_3$$

In Step A of Reaction Scheme I, a displacement reaction is carried out between phosgene (2, Y = Cl) or

triphosgene (2, $Y = \text{OCCl}_3$) and a functionalized amino acid as described by structure (1) in which A is as in Formula I and Pr is a t-butyloxycarbonyl group, while Pr' is a t-butyl group. This displacement reaction produces a chloroformate or a trichloromethylurethane as described by structure (3) in which Pr, Pr' and A are as defined above. In Step B, the chloroformate of structure (3, $Y = \text{Cl}$) or the trichloromethylurethane (3, $Y = \text{OCCl}_3$) is subjected to an amidation reaction with an amino-derivative as described by structure (4) in which X is as defined in Formula Ia, thereby producing the protected compound of Formula Ia'. In Step C, the protecting groups Pr and Pr' are removed thus producing a compound of Formula Ia. In Step D, an optional functionalization reaction can be carried out in order to introduce the appropriate R substituent into the molecule at the position indicated.

The displacement reaction of Step A can be carried out using techniques well known in the art. The particular functionalized amino acid of structure (1) which is utilized as a starting material should have the same function at the A position as is desired in the final product of Formula Ia. Typically approximately equivalent amounts of the amino acid of structure (1) and the phosgene or triphosgene are contacted in an organic solvent such as benzene, toluene or methylene dichloride at a temperature range of from about -10°C to about 60°C . The displacement reaction is typically allowed to proceed for a period of time ranging from about 0.5 to 2 hours.

A molar excess of the amino derivative of structure (4) is then added to the reaction medium in which the displacement was carried out. The amidation reaction of Step B is then allowed to proceed for a period of time ranging from about 0.5 to 8 hours. The amidation reaction is carried out at a temperature range of from about $0-40^\circ\text{C}$. Upon completion of the amidation reaction, the desired product can be recovered from the reaction medium by extraction or concentration. It can optionally be purified by flash chromatography as is known in the art. The particular amino-derivative of structure (4) which is utilized as a reactant should have the same substituent at the X position as is desired in the final product of Formula I.

The deprotection reaction of Step C can be carried out using techniques well known in the art. This deprotection reaction produces a compound of Formula Ia in which R is represented by a hydroxyl group as is depicted. The protected compound of Formula Ia' is typically subjected to a mildly acidic hydrolysis with a mineral acid such as hydrochloric acid. The concentration of acid which is utilized is not critical and typically is in the range of from about 1-4 M. The deprotection reaction is typically carried out for a period of time ranging from about 0.25-4 hours at a temperature range of from $0-60^\circ\text{C}$. The compound of Formula Ia can be recovered from the reaction medium by either concentration or extraction as is known in the art. It can then be purified by either ion exchange chromatography or by preparative C_{18} reverse phase chromatography as is known in the art.

If R is to be represented by other than a hydroxyl group, then it is necessary carry out the optional functionalization reaction of Step D. The various ester derivatives of Formula Ia can be prepared utilizing techniques well known in the art. For example if an ester is desired, the deprotected compound of Formula Ia can be contacted with an alcohol corresponding to the desired substituent in the presence of a mineral acid. If R is to be represented by an amino acid, then it can be added to the compounds of Formula I utilizing peptide coupling techniques known in the art. For example, see Meldal et al. Synthesis of a Proposed Antigenic Hexapeptide from Escheria Coli K88 Protein Fimbriae-- *Acta Chem. Scand.* B40: 235-241.

Methods for producing the functionalized amino acids of structure (1) are well known in the art. For example, the preparation of 5-hydroxynorvaline is described in *J. Chem. Soc., Chem. Commun.*, 20, 1583-4 (1987) and the preparation of 6-hydroxynorleucine is described in *Agric. Biol. Chem.*, 42(6), 1275-8 (1979). Methods for producing the amino derivatives of structure (4) are also well known in the art.

The following examples represent typical syntheses of compounds of formula (Ia). These examples are understood to be illustrative only and are not intended to limit the scope of the present invention in any way.

Example 1

Preparation of O-[Hydrazino-carbonyl]-5-hydroxynorvaline

Step A: 2-(N-t-Butyloxycarbonylamino)-5-(O-chloroformate)-5-hydroxynorvaline, t-butyl ester

Dissolve 5-hydroxynorvaline (13.3g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl bromide (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60°C to give the copper complex. Suspend the copper

complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give O-benzyl-5-hydroxynorvaline.

- Suspend O-benzyl-5-hydroxynorvaline (67g, 0.3mol) in t-butyl acetate (250mL) and cool to 10° C. Add
 5 p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10° C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO₄), and evaporate to give O-benzyl-5-hydroxynorvaline, t-butyl ester.

- Dissolve O-benzyl-5-hydroxynorvaline, t-butyl ester (2.79g, 10mmol) in 50/50 dioxane/water (25mL) and
 10 buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10° C. Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO₄) and blow to a residue with a stream of nitrogen to give N-t-butyloxycarbonyl-O-benzyl-5-hydroxynorvaline, t-butyl ester.

- Mix N-t-butyloxycarbonyl-O-benzyl-5-hydroxynorvaline, t-butyl ester (2.0g, 5.3mmol) and 10%
 15 palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxy-5-hydroxynorvaline, t-butyl ester.

- Dissolve N-t-butyloxy-5-hydroxynorvaline, t-butyl ester (2.89g, 10mmol) in methylene dichloride (50mL),
 20 place under a nitrogen atmosphere and cool to 0° C. Add phosgene (1.0g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

Step B: N-t-Butyl-5-(hydrazinoamide)-5-hydroxynorvaline, t-butyl ester

- Add hydrazine (0.5g, 15mmol) to 2-(N-t-butyloxycarbonylamino)-5-(O-chloroformate)-5-hydroxynorvaline,
 25 t-butyl ester (3.51g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO₄). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give the title compound.

30 Step C: O-[Hydrazino-carbonyl]-5-hydroxynorvaline

- Mix N-t-butyl-5-(hydrazinoamide)-5-hydroxynorvaline, t-butyl ester (3.47g, 10mmol) and 1N hydrochloric
 acid (50mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction
 mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), the
 35 neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatog-raphy to give the title compound.

Example 2

40 Preparation of O-(Cyclopropylamino-carbonyl)-6-hydroxynorleucine

Step A: 2-(N-t-Butyloxycarbonylamino)-6-(O-chloroformate)-6-hydroxynorleucine, t-butyl ester

- Dissolve 6-hydroxynorleucine (14.7g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution
 45 of CuSO₄ · 5H₂O (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl bromide (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60° C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter.
 50 Wash the residue with water and dry to give O-benzyl-6-hydroxynorleucine.

- Suspend O-benzyl-6-hydroxynorleucine (71.2g, 0.3mol) in t-butyl acetate (250mL) and cool to 10° C. Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10° C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO₄), and evaporate to give O-benzyl-6-hydroxynorleucine, t-butyl
 55 ester.

Dissolve O-benzyl-6-hydroxynorleucine, t-butyl ester (2.93g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10° C. Allow to warm to room temperature and buffer occasionally to retain

pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO_4) and blow to a residue with a stream of nitrogen to give N-t-butyloxycarbonyl-O-benzyl-6-hydroxynorleucine, t-butyl ester.

Mix N-t-butyloxycarbonyl-O-benzyl-6-hydroxynorleucine, t-butyl ester (2.0g, 5.1mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxy-6-hydroxynorleucine, t-butyl ester.

Dissolve N-t-butyloxy-6-hydroxynorleucine, t-butyl ester (3.03g, 10mmol) in methylene dichloride (50mL), place under a nitrogen atmosphere and cool to 0 °C. Add phosgene (1.0g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

10

Step B: N-t-Butyl-6-(cyclopropylamide)-6-hydroxynorleucine, t-butyl ester

Add cyclopropylamine (0.86g, 15mmol) to 2-(N-t-butyloxycarbonylamino)-6-(O-chloroformate)-6-hydroxynorleucine, t-butyl ester (3.65g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO_4). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give the title compound.

20

Step C: O-(Cyclopropylamino-carbonyl)-6-hydroxynorleucine

Mix N-t-butyl-6-(cyclopropylamide)-6-hydroxynorleucine, t-butyl ester (3.86g, 10mmol) and 1N hydrochloric acid (50mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), then neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

25

Example 3

Preparation of O-[Hydrazino-carbonyl]-2-amino-5-hydroxy-3-pentenoic acid

30

Step A: 2-(N-t-Butyloxycarbonylamino)-5-(O-chloroformate)-3-pentenoic acid, t-butyl ester

Dissolve dimethyl 2-acetamido-2-(3-hydroxy-1-propene) malonate (*Tetrahedron. Lett.*, 29(47), 6183-4 (1988) (2.45g, 10mmol) in tetrahydrofuran (30mL). Treat with 1N sodium hydroxide and stir at room temperature until hydrolysis of the esters is complete. Acidify with 5N hydrochloric acid and stir at 50 °C until decarboxylation is complete. Cool to room temperature pour into methylene chloride and separate the organic phase. Extract the aqueous phase with methylene chloride (2X), dry (MgSO_4) and evaporate the solvent *in vacuo* to give 5-hydroxy-2-(acetamido)-3-pentenoic acid.

Mix 5-hydroxy-2-(acetamido)-3-pentenoic acid (1.73g, 10mmol) and acylase (I) (Merck) in pH 7.2 buffer and stir at 37 °C until hydrolysis is complete. Purify by ion exchange chromatography to give 5-hydroxy-2-amino-3-pentenoic acid.

Dissolve 5-hydroxy-2-amino-3-pentenoic acid (13.1g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl bromide (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60 °C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give O-benzyl-5-hydroxy-2-amino-3-pentenoic acid.

Suspend O-benzyl-5-hydroxy-2-amino-3-pentenoic acid (66.4g, 0.3mol) in t-butyl acetate (250mL) and cool to 10 °C. Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10 °C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO_4), and evaporate to give O-benzyl-5-hydroxy-2-amino-3-pentenoic acid, t-butyl ester.

Dissolve O-benzyl-5-hydroxy-2-amino-3-pentenoic acid, t-butyl ester (2.77g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10 °C. Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO_4) and blow to a residue with a stream of nitrogen to give 2-(N-t-butyloxycarbonylamino)-5-(O-

benzyloxy)-3-pentenoic acid, t-butyl ester.

Mix 2-(N-t-butyloxycarbonylamino)-5-(O-benzyloxy)-3-pentenoic acid, t-butyl ester (2.0g, 5.3mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give 2-(N-t-butyloxycarbonylamino)-5-hydroxy-3-pentenoic acid, t-butyl ester.

Dissolve 2-(N-t-butyloxycarbonylamino)-5-hydroxy-3-pentenoic acid, t-butyl ester (2.87g, 10mmol) in methylene dichloride (50mL), place under a nitrogen atmosphere and cool to 0 °C. Add phosgene (1.0g, 10mmol) and allow to stir at room temperature for 2 hours to give the title compound .

10 Step B: 5-(O-Hydrazinoamide)-2-(N-t-butyloxyamino)-5-hydroxy-3-pentenoic acid, t-butyl ester

Add hydrazine (0.5g, 15mmol) to 2-(N-tert-butyloxycarbonylamino)-5-(O-chloroformate)-3-pentenoic acid, t-butyl ester (3.5g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO₄). Evaporate the solvent *in vacuo* and purify the by silica gel chromatography to give the title compound.

Step C: O-[Hydrazino-carbonyl]-2-amino-5-hydroxy-3-pentenoic acid

Mix 5-(O-hydrazinoamide)-2-(N-t-butyloxyamino)-5-hydroxy-3-pentenoic acid, t-butyl ester (3.45g, 10mmol) and 1N hydrochloric acid (50mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), the neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

Those compounds of Formula Ib in which Z is represented by NR₁ can also be made using techniques known in the art. Reaction Scheme II shows one method by which these compounds can be produced.

30

35


40

45

50

55

REACTION SCHEME II



In Step A, a displacement reaction is carried out between a functionalized amino acid as described by structure (5) and an amidino derivative as described by structure (6). In the amidine structure (6), Alk is represented by a C₁₋₄ alkyl, and R₁ and X are as defined in Formula Ia. This displacement reaction produces the optionally protected compound which has been depicted as Ib'. In step B, the protecting groups, if present, are removed via an acidic hydrolysis and in Step C the appropriate R substituent may be placed on the molecule as is depicted.

50 The displacement reaction of Step A can be carried out using techniques well known in the art. The meanings for Pr and Pr' should be complementary (i.e. both should be hydrogen, organic residues or copper). The appropriate amidine (6) is one in which X is represented by the substituent which is desired in the final product. The linear C₁₋₄ alkyl represented by Alk is not retained in the final product, and thus its identity is immaterial.

55 The particular manner in which the displacement reaction is carried out depends upon the particular substituent which is present at the Pr and Pr' position. If Pr and Pr' are represented by organic protecting groups, then the reaction is carried out by contacting approximately equivalent amounts of the functionalized amino acid and the amidino-derivative in an aprotic solvent such as dimethylformamide at a

temperature range of from room temperature to about 80° C. The reaction is typically allowed to proceed for a period of time ranging from about 8 hours to about 120 hours. Upon completion of the reaction, the functionalized amino acid of Formula Ib' can be recovered by either concentration or extraction as is known in the art. It can then be optionally purified by flash chromatography. In Step B these protecting groups are removed by an acidic hydrolysis. This hydrolysis can be carried out in the same manner as the deprotection reaction of Reaction Scheme I. The deprotected compound of Formula Ib can be purified by either ion exchange chromatography or by preparative C₁₈ reverse phase chromatography. Likewise, the appropriate R substituent may be placed on the compound of Formula Ib utilizing the same methods as taught in Reaction Scheme I.

If Pr and Pr' are represented by either hydrogen atoms or by a copper complex, then the displacement reaction is carried out in the following manner. Approximately equivalent amounts of the functionalized amino acid of structure (5) and the amidino derivative of structure (6) are contacted in a dilute solution of an inorganic base such as sodium hydroxide. The displacement reaction is carried out at about 40° C for a period of time ranging from about 8 to 120 hours. The desired product of Formula Ib can then be recovered from the reaction by either extraction or concentration as is known in the art. This crude product can then be purified by ion exchange chromatography or by preparative C₁₈ reverse phase chromatography.

Methods for preparing the functionalized amino acids of structure (5) are well known in the art. For example, 5-amino-2-(N-acetylamino)-3-pentenoic acid is described in *Tetrahedron Letters*, 29(47), 6183-4 (1988). Methods for preparing the amidino derivatives of structure (6) are also well known in the art. For examples, see G.V. Nair, *Ind. J. Chem.*, 4, 516 (1966).

The following example presents a typical synthesis as described above in Scheme II. This example is understood to be illustrative only and is not intended to limit the scope of the present invention in any way.

Example 4

Preparation of N⁵-[Hydrazino-iminomethyl]-2,5-diamino-3-pentenoic acid


Step A: N⁵-[Hydrazino-iminomethyl]-2-(acetylamino)-5-amino-3-pentenoic acid

Mix 5-amino-2-(N-acetylamino)-3-pentenoic acid HCl (4.16g, 20mmol) and S-methylisothiosemicarbazide (2.11g, 20mmol) in 1N NaOH (40mL) and stir under a blanket of N₂ at 40° C for 48 hours. Cool the reaction to room temperature, neutralize with 1N HCl and blow to a residue with a stream of N₂ to give the title compound.

Step B: N⁵-[Hydrazino-iminomethyl]-2,5-diamino-3-pentenoic acid

Mix N⁵-[hydrazino-iminomethyl]-2-(acetylamino)-5-amino-3-pentenoic acid (4.6g, 20mmol) and acylase (I) (Merck) in pH 7.2 buffer and stir at 37° C until hydrolysis is complete. Purify by ion exchange chromatography to give the title compound.


Alternatively, those compounds of Formula Ib in which Z is represented by O can be made utilizing the methods disclosed in Reaction Scheme IV. The only modification is that the functionalized amino acid that is utilized as one of the starting materials should have a double bond connecting the α and β carbon atoms. This starting material may be represented by the following formula:



in which Pr and Pr' are as above.

Those compounds of Formula Ic in which Z is represented by NR₁ can also be made using techniques known in the art. Reaction Scheme III shows one method by which these compounds can be produced.

REACTION SCHEME III



In Step A, a displacement reaction is carried out between a functionalized amino acid as described by structure (7) and an amidino derivative as described by structure (6). In structure (7), W' is represented by -CH₂-NH₂, -NH-NH₂, -CH₂-O-NH₂, -CH₂-NH-NH₂, -(CH₂)₂-NH₂ or -O-NH₂. If W' is represented by -CH₂-NH then Pr and Pr' may both be hydrogen or copper. Alternatively Pr' is t-butyl while Pr is t-butyloxycarbonyl. If W' is either NH₂-NH₂, -CH₂-O-NH₂, -CH₂-NH-NH₂, or -O-NH₂, then Pr and Pr' may both be copper, or Pr' is ethyl while Pr is a benzyloxycarbonyl. In structure (6), Alk is represented by a C₁₋₄ alkyl, and R₁ and X are as defined in Formula Ic. This displacement reaction produces the optionally protected compound which has been depicted as Ic'. In step B, the protecting groups, if present, are removed via an acidic hydrolysis and in Step C the appropriate R substituent may be placed on the molecule as is depicted.

The displacement reaction of Step A can be carried out using techniques well known in the art. The appropriate functionalized amino acid of structure (7) is one in which W' corresponds to the substituent which is desired at this position in the final product (ie. if W is to be represented by -CH₂-NH-, then W' should be represented by -CH₂-NH₂). The meanings for Pr and Pr' should be complementary (ie. both should be hydrogen, organic residues or copper). The appropriate amidine is one in which X is represented by the substituent which is desired in the final product. The linear C₁₋₄ alkyl represented by Alk is not

retained in the final product, and thus its identity is immaterial.

The particular manner in which the displacement reaction is carried out depends upon the particular substituent which is present at the Pr and Pr' position. If Pr and Pr' are represented by organic protecting groups, then the reaction is carried out by contacting approximately equivalent amounts of the functionalized amino acid and the amidino-derivative in an aprotic solvent such as dimethylformamide at a temperature range of from room temperature to about 80° C. The reaction is typically allowed to proceed for a period of time ranging from about 8 hours to about 120 hours. Upon completion of the reaction, the functionalized amino acid of formula Ic' can be recovered by either concentration or extraction as is known in the art. It can then be optionally be purified by flash chromatography. In Step B these protecting groups are removed by an acidic hydrolysis. This hydrolysis can be carried out in the same manner as the deprotection reaction of Reaction Scheme I. The deprotected compound of Formula Ic can be purified by either ion exchange chromatography or by preparative C₁₈ reverse chromatography. Likewise, the appropriate R substituent may be placed on the compound of Formula Ic utilizing the same methods as taught in Reaction Scheme I.

If Pr and Pr' are represented by either hydrogen atoms or by a copper complex then the displacement reaction is carried out in the following manner. Approximately equivalents amounts of the functionalized amino acid of structure (7) and the amidino derivative of structure (6) are contacted in a dilute solution of an inorganic base such as sodium hydroxide. The displacement reaction is carried out at about 40° C for a period of time ranging from about 8 to 120 hours. The desired product of Formula Ic can then be recovered from the reaction by either extraction or concentration as is known in the art. This crude product can then be purified by ion exchange chromatography or by preparative C₁₈ reverse chromatography.

Methods for producing the functionalized amino acids of structure (7) are known in the art. For example, the preparation of canaline is described in *J. Am. Chem. Soc.*, 79, 1222 (1957).

The following examples represent typical syntheses as described above in Scheme III. These examples are intended to be illustrative only and are not intended to limit the scope of the present invention in any way.

Example 5

Preparation of N⁵-(Hydrazino-methyliminomethyl)-L-ornithine, flavinate

This example demonstrates the preparation of a compound according to formula Ic in which Z is N, utilizing the methodology of Reaction Scheme III.

L-Ornithine HCl (3.36g, 20mmol) and S-methyl-4-methylisothiosemicarbazide hydroiodide (5.00g, 20mmol) in 1M NaOH (40ml) were mixed and stirred under a blanket N₂ at 40° C (for 48 hours). The reaction was then neutralized with 1M HCl and blown to a residue with a stream of N₂. The residue was applied to a Dowex AG50-X8 column and eluted with 0.2M NH₄OH. The fractions containing the desired product were lyophilized and the resulting solid taken up in water (20ml). Flavianic acid (3.2g) in water (20ml) was added and the solution cooled to 4° C for 16 hours. The resulting solid was filtered and crystallized from water to yield 1.3g of the title compound as a yellow solid. ¹HNMR (300 MHz, δ_c DMSO) 1.45 (2,m) 1.78 (2,m) 2.85 (3,s) 3.15 (2m) 3.85 (1,t) 7.8 (1,m) 8.6-8.8 (2,m) 9.2 (1,s). Anal. Calcd. for C₁₇H₂₃N₇O₁₀S: C, 39.46; H, 4.48; N, 18.95. Found C, 38.56; H, 4.48; N, 18.95.

Example 6

Preparation of N⁵-[Imino(cyclopropyl)methyl]-L-ornithine, flavinate

This example also demonstrates the methodology of Reaction Scheme III.

t-Butyl isothiocyanate (11.6ml, 0.1mol) and cyclopropylamine (6.9ml, 0.1mol) were mixed in toluene (200ml) and stirred at room temperature overnight. The resulting mixture was evaporated to a residue and crystallized from cyclohexane to yield N-cyclopropyl-N-butyl thiourea. N-cyclopropyl-N-t-butyl thiourea (5g) was suspended in 5M HCl (50ml) and heated to 80° C for 10 minutes. The resulting solution was cooled, poured into a saturated sodium bicarbonate (250ml), and extracted with ethyl acetate (2x125ml). The solution was dried (MgSO₄), evaporated to a residue and crystallized from ethyl acetate to yield a white solid, cyclopropyl thiourea, 110mg.

Cyclopropyl thiourea (0.65g, 0.0056mol) and iodomethane (1.2g, 0.0085mol) were mixed in acetone, heated to boiling and refluxed for 15 minutes. The reaction was cooled and blown to an oil. Ethyl acetate (10ml) was added, and the resulting mixture was blown to a white solid. L-Ornithine*HCl (0.94g, 0.0056mol)

and 1M NaOH (15ml) were added and the resulting reaction warmed to 40 °C and stirred under a blanket of N₂ for 16 hours. The reaction mixture was cooled to room temperature, acidified with acetic acid and blown with a stream of N₂ to 1/2 volume. Flavianic acid (1g) in water (10ml) was added and the resulting solid filtered, dried and recrystallized from boiling water to yield 1.4g of the title compound which appeared as a yellow solid. ¹HNMR (d₆DMSO) 0.52 (2,m) 0.82 (2,m) 1.45 (2m) 1.78 (2,m) 2.5 (1,m) 3.15 (2,m) 3.85 (1,m) 7.8 (1,m) 8.1-8.8 (2,m) 9.2 (1,s). Anal Calcd. for C₉H₁₈N₄O₂·C₁₀H₆N₂O₈S·1/2H₂O: C, 41.97; H, 4.64; N, 15.76. Found C, 42.67; H, 4.56; N, 15.76.

Example 7

Preparation of N⁵-[Hydrazino-iminomethyl]-canaline, flavinate

Mix canaline (2.65g, 20mmol) and S-methyl-isothiosemicarbazide hydroiodide (4.66g, 20mmol) in 1M NaOH (40ml) and stir under a blanket N₂ at 40 °C for 48 hours. Neutralize the reaction with 1M HCl and blow to a residue with a stream of N₂. Apply the residue to a Dowex AG50-X8 column and elute with 0.2M NH₄OH. Lyophilize the fractions containing the desired product and take up the resulting solid in water (20ml). Add flavianic acid (3.2g) in water (20ml) and cool the solution to 4 °C for 16 hours. Filter the resulting solid and crystallize to yield the title compound.

Example 8

Preparation of N⁶-(Hydrazino-iminomethyl)-lysine, flavinate

Mix lysine HCl (3.65g, 20mmol) and S-methyl-isothiosemicarbazide hydroiodide (4.66g, 20mmol) and adjust to pH 10 with 1M NaOH. Stir under a blanket N₂ at 40 °C for 48 hours. Neutralize the reaction with 1M HCl and blow to a residue with a stream of N₂. Apply the residue to a Dowex AG50-X8 column and elute with 0.2M NH₄OH. Lyophilize the fractions containing the desired product and dissolve the resulting solid in water (20ml). Add a solution of flavianic acid (3.2g) in water (20ml) and cool to 4 °C for 16 hours. Filter the resulting solid and crystallize from water to yield 1.2g of the title compound. ¹HNMR (d₆DMSO) 1.3-1.6 (4,m), 1.85 (2,m), 3.15 (2,m), 3.95 (1,t), 8.05 (2,m), 8.8 (3,m), 9.2 (1,m); ¹³CNMR (d₆DMSO) 22.3, 28.7, 30.2, 41.04, 52.0, 57.4, 124.7, 125.2, 129.1, 129.6, 130.3, 130.7, 132.0, 144.5, 158.8, 168, 172.1, 174.1.

Example 9

Preparation of N⁷-[Hydrazino-iminomethyl]-2-amino-5-aminooxy-pentanoic acid

Dissolve 5-hydroxynorvaline (20g, 0.15mol) in water (90mL) and add anhydrous potassium carbonate (10.4g, 0.075mol) with stirring. Heat the slightly alkaline solution on a steam-bath for a few minutes, then add a solution of potassium cyanate (13.0g, 0.16mol) in water (50mL). Heat the final solution on a steam-bath for 2 hours. Treat the solution with 48% hydrobromic acid (100mL) and heat for an additional 2 hours on the steam-bath. Evaporate the solvent *in vacuo* and digest the residue with hot acetone (150mL) and filter. Wash the potassium bromide residue with hot acetone until white. Evaporate the acetone filtrate and heat the residue with additional 48% hydrobromic acid for 2 hours on the steam-bath. Evaporate the solvent *in vacuo*, dissolve the residue in hot water (75mL), bring to pH 5-6 with concentrated ammonia, filter, cool and collect 5-(3-bromopropyl)-hydantoin.

Dissolve 85% potassium hydroxide (3.96g, 60mmol) in absolute ethanol (60mL). Add 5-(3-bromopropyl)-hydantoin (6.63g, 30mmol) and a solution of hydroxyurethane (6.30g, 60mmol) in absolute ethanol (40mL). Reflux for 3 hours, cool and filter to remove potassium bromide. Evaporate the solvent *in vacuo*, dissolve the residue in water (30mL), neutralize with dilute hydrochloric acid, cool and collect 5-[3-(carbethoxyaminooxy)-propyl]-hydantoin.

Mix 5-[3-(carbethoxyaminooxy)-propyl]-hydantoin (2.45g, 10mmol), barium hydroxide octahydrate (18.15g, 10mmol) and water (55mL). Reflux for 12 hours, remove the white solid by filtration, extract the filter cake with boiling water (25ml) and finally wash with hot water (25mL). Combine the filtrate and washings, treat with ammonium carbonate (5.7g) and heat with stirring. Filter off the barium carbonate, wash the filter cake with hot water and evaporate the filtrate and washings *in vacuo* to give 2-amino-5-aminooxy-pentanoic acid.

Mix 2-amino-5-aminooxy-pentanoic acid (2.97g, 20mmol) and S-methyl-isothiosemicarbazide hydroiodide (4.66g, 20mmol) in 1M NaOH (40ml) and stir under a blanket N₂ at 40 °C for 48 hours.

Neutralize the reaction with 1M HCl and blow to a residue with a stream of N₂. Apply the residue to a Dowex AG50-X8 column and elute with 0.2M NE₄ OH. Lyophilize the fractions containing the desired product and take up the resulting solid in water (20ml). Add flavianic acid (3.2g) in water (20ml) and cool the solution to 4 °C for 16 hours. Filter the resulting solid and crystallize to yield the title compound.


- 5 An alternative method for producing the compounds of Formula Ic in which Z is represented by NR₁ and R₁ is hydrogen, is to carry out a displacement reaction between a functionalized amino acid as described by structure (7) in which Pr and Pr' are represented by protecting groups and an amino nitrile of the Formula, X-NH-CN, in which X is as defined in Formula Ic. This displacement reaction produces the protected compound of Formula Ic' disclosed above in Reaction Scheme III. This displacement can be carried out by contacting equivalent amounts of the reactants in an aprotic solvent such as toluene or benzene at a temperature of about -5 °C to reflux for a period of time ranging from about 1 hour to 16 hours. The compound of Formula Ic' can be recovered by either extraction or concentration. It can then be purified by ion exchange chromatography or preparation C₁₈ reverse phase chromatography. The desired compounds of Formula Ic can then be produced via the deprotection reaction and optional functionalization reactions taught in steps B and C of Reaction Scheme II.

Those compounds of Formula Ic in which Z is represented by O can also be produced by methods known in the art. One such method is disclosed below in Reaction Scheme IV:

REACTION SCHEME IV


STEP A

ADDITION




DEPROTECTION

STEP B



STEP C


OPTIONAL FUNCTIONALIZATION



In Step A an addition reaction is carried out between a functionalized amino acid as described by structure (7) in which Pr, Pr' and W are as defined in Reaction Scheme III, and an isocyanate derivative as described by structure (8) in which X is as defined in Formula Ic and Z is O as is depicted. This addition reaction produces the protected compound of Formula Ic'. The deprotection reaction of Step B produces the desired compound of Formula Ic. If desired this compound can be subjected to the optional functionalization reaction of Step C.

The appropriate isocyanate derivative is one in which X is represented by the same substituent as is desired in the final product of Formula Ic. The addition reaction of Step A can be carried out using techniques well known in the art. Typically approximately equivalent amounts of the reactants are contacted in an organic solvent such as toluene, benzene, or methylene dichloride at a temperature range of from -10° C to about 80° C for a period of time ranging from about 1 to 16 hours. The protected compound of Formula Ic' can then be recovered from the reaction by either concentration or extraction as is known. It can then be purified by flash chromatography. The deprotection reaction of Step B and the optional functionalization reaction of Step C can be carried out using the methods taught in the previous Reaction Schemes.

Those compounds of Formula Ic in which Z is represented by O and W is represented by either -CH₂-NH- or -(CH₂)₂-NH- can also be made by the following alternative method. A displacement reaction is carried out between phosgene (previous structure 2 of Reaction Scheme I, Y=Cl) or triphosgene (previous structure 2 of Reaction Scheme I, Y=OCCl₃) and a functionalized amino acid of the formula: in which W' is represented by either -CH₂-NH₂ or -(CH₂)₂-NH₂ and in which Pr and Pr' are as defined above Reaction Scheme



I. This displacement reaction can be carried out using techniques known in the art. Typically approximately equivalent amounts of the reactants are contacted in an organic solvent solvent such as toluene, benzene or methylene dichloride at a temperature range of from -10° C to 60° C. The reaction is usually allowed to proceed for a period of time ranging from about 1 to 16 hours At this point, a molar excess of an amine of the formula, NH₂X, in which X is as defined in Formula Ic, is added to the reaction. The reactants are heated to a temperature range of -10° C to 60° C for a period of time ranging from 1 to 16 hours. This reaction produces a product which can be described by Formula Ic' in Reaction Scheme III in which W is represented by CH₂-NH, and X, Pr and Pr' are as above, and Z is represented by O as is depicted. These compounds can then be subjected to a deprotection reaction and an optional functionalization reaction in the same manner as disclosed in Reaction Scheme III.

The following examples represent typical syntheses as described above for compounds of formula Ic, wherein Z is O, W is -(CH₂)₂-NH-, and X is NH₂. These examples are intended to be illustrative only and are not intended to limit the scope of the present invention in any way.

Example 10

Preparation of N⁵-(Hydrazino-carbonyl)-ornithine

Step A: N-t-Butyloxycarbonyl-N⁵-(trichlormethylcarbonate)-ornithine, t-butyl ester

Dissolve ornithine (13.3g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of CuSO₄ · 5H₂O (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl chloroformate (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60° C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give N⁵-benzyloxycarbonyl-ornithine.

Suspend N⁵-benzyloxycarbonyl-ornithine (80g, 0.3mol) in t-butyl acetate (250mL) and cool to 10° C. Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10° C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in

water. Extract with ethyl acetate, dry (MgSO_4), and evaporate to give N^5 -benzyloxycarbonyl-ornithine, t-butyl ester.

Dissolve N^5 -benzyloxycarbonyl-ornithine, t-butyl ester (3.22g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10°C . Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO_4) and blow to a residue with a stream of nitrogen to give N-t-butyloxycarbonyl- N^5 -benzyloxycarbonyl-ornithine, t-butyl ester.

Mix N-t-butyloxycarbonyl- N^5 -benzyloxycarbonyl-ornithine, t-butyl ester (2.0g, 5.0mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxycarbonyl-ornithine, t-butyl ester.

Dissolve N-t-butyloxycarbonyl-ornithine, t-butyl ester (2.88g, 10mmol) in methylene dichloride (30mL), place under a nitrogen atmosphere and cool to 0°C . Add triphosgene (2.81g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

Step B: N^2 -t-Butyl- N^5 -hydrazinoamide-ornithine, t-butyl ester

Add hydrazine (0.5g, 15mmol) to N-t-butyloxycarbonyl- N^5 -(trichloromethylcarbonate)-ornithine, t-butyl ester (4.5g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO_4). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give title compound.

Step C: N^5 -(Hydrazino-carbonyl)-ornithine

Mix N^2 -t-butyl- N^5 -hydrazinoamide-ornithine, t-butyl ester (3.46g, 10mmol) and 1N hydrochloric acid (30mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), the neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

Example 11

Preparation of N^6 -(Hydrazino-carbonyl)-lysine

Step A: N-t-Butyloxycarbonyl- N^6 -(trichloromethyl-carbonate)-lysine, t-butyl ester

Dissolve lysine (14.6g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl chloroformate (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60°C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give N^5 -benzyloxycarbonyl-lysine.

Suspend N^5 -benzyloxycarbonyl-lysine (84.1g, 0.3mol) in t-butyl acetate (250mL) and cool to 10°C . Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10°C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO_4), and evaporate to give N^5 -benzyloxycarbonyl-lysine, t-butyl ester.

Dissolve N^5 -benzyloxycarbonyl-lysine, t-butyl ester (3.36g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10°C . Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO_4) and blow to a residue with a stream of nitrogen to give N-t-butyloxycarbonyl- N^5 -benzyloxycarbonyl-lysine, t-butyl ester.

Mix N-t-butyloxycarbonyl- N^5 -benzyloxycarbonyl-lysine, t-butyl ester (2.0g, 4.6mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxycarbonyl-lysine, t-butyl ester.

Dissolve N-t-butyloxycarbonyl-lysine, t-butyl ester (3.02g, 10mmol) in methylene dichloride (30mL), place under a nitrogen atmosphere and cool to 0 °C. Add triphosgene (2.81g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

5 Step B: N²-t-Butyl-N⁵-hydrazinoamide-lysine, t-butyl ester

Add hydrazine (0.5g, 15mmol) to N-t-butyloxycarbonyl-N⁶-(trichloromethyl-carbonate)-lysine, t-butyl ester (4.64g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic
10 phases with saturated sodium chloride and dry (MgSO₄). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give the title compound.

Step C: N⁶-(Hydrazino-carbonyl)-lysine

15 Mix N²-t-butyl-N⁵-hydrazinoamide-lysine, t-butyl ester (3.60g, 10mmol) and 1N hydrochloric acid (30mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), then neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

20

Example 12

Preparation of N⁵-[Cyclopropylamino-carbonyl]-2-amino-4-hydrazino-butanoic acid

25 Step A: N-t-Butyloxycarbonyl-2-amino-4-[(trichloromethylcarbonate)hydrazino]-butanoic acid, t-butyl ester

Dissolve homoserine (17.9g, 0.15mol) in water (90mL) and add anhydrous potassium carbonate (10.4g, 0.075mol) with stirring. Heat the slightly alkaline solution on a steam-bath for a few minutes, then add a solution of potassium cyanate (13.0g, 0.16mol) in water (50mL). Heat the final solution on a steam-bath for 2
30 hours. Treat the solution with 48% hydrobromic acid (100mL) and heat for an additional 2 hours on the steam-bath. Evaporate the solvent *in vacuo* and digest the residue with hot acetone (150mL) and filter. Wash the potassium bromide residue with hot acetone until white. Evaporate the acetone filtrate and heat the residue with additional 48% hydrobromic acid for 2 hours on the steam-bath. Evaporate the solvent *in vacuo*, dissolve the residue in hot water (75mL), bring to pH 5-6 with concentrated ammonia, filter, cool and
35 collect 5-(2-bromoethyl)-hydantoin.

Dissolve 85% potassium hydroxide (3.96g, 60mmol) in absolute ethanol (60mL). Add 5-(2-bromoethyl)-hydantoin (6.21g, 30mmol) and a solution of ethyl carbazate (6.3g, 60mmol) in absolute ethanol (40mL). Reflux for 3 hours, cool and filter to remove potassium bromide. Evaporate the solvent *in vacuo*, dissolve the residue in water (30mL), neutralize with dilute hydrochloric acid, cool and collect 5-(2-
40 (carbethoxyhydrazino)-ethyl)-hydantoin.

Mix 5-[(2-(carbethoxyhydrazino)-ethyl)]-hydantoin (2.3g, 10mmol), barium hydroxide octahydrate (18.15g, 10mmol) and water (55mL). Reflux for 12 hours, remove the white solid by filtration, extract the filter cake with boiling water (25mL) and finally wash with hot water (25mL). Combine the filtrate and washings, treat with ammonium carbonate (5.7g) and heat with stirring. Filter off the barium carbonate, wash
45 the filter cake with hot water and evaporate the filtrate and washings *in vacuo* to give 2-amino-4-hydrazino-butanoic acid.

Dissolve 2-amino-4-hydrazino-butanoic acid (13.3g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of CuSO₄ · 5H₂O (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl chloroformate (17.1g, 0.1mol) and stir at room temperature until reaction is complete.
50 Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60 °C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid.

55 Suspend N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid (80.2g, 0.3mol) in t-butyl acetate (250mL) and cool to 10 °C. Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10 °C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO₄), and evaporate to give

N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester.

Dissolve N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester (3.23g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to pH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10° C. Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO₄) and blow to a residue with a stream of nitrogen to give N-tert-butyloxycarbonyl-N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester.

Mix N-t-butyloxycarbonyl-N⁵-benzyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester (2.11g, 5.0mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester.

Dissolve N-t-butyloxycarbonyl-2-amino-4-hydrazino-butanoic acid, t-butyl ester (2.88g, 10mmol) in methylene chloride (30mL), place under a nitrogen atmosphere and cool to 0° C. Add triphosgene (2.81g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

15 Step B: N²-t-Butyloxycarbonyl-N⁶-(cyclopropylamino-carbonyl)-2-amino-4-hydrazino-butanoic acid, t-butyl ester

Add cyclopropylamine (0.86g, 15mmol) to N-t-butyloxycarbonyl-2-amino-4-[(trichloromethylcarbonate)-hydrazino]-butanoic acid, t-butyl ester (4.5g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO₄). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give the title compound.

25 Step C: N⁵-[Cyclopropylamino-carbonyl]-2-amino-4-hydrazino-butanoic acid

Mix N²-t-butyloxycarbonyl-N⁶-(cyclopropylamino-carbonyl)-2-amino-4-hydrazino-butanoic acid, t-butyl ester (3.72g, 10mmol) and 1N hydrochloric acid (30mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), the neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

Example 13

35 Preparation of N⁷-(Cyclopropylamino-carbonyl)-2-amino-5-hydrazino-pentanoic acid

Step A: N-t-Butyloxycarbonyl-2-amino-5-[(trichloromethylcarbonate)hydrazino]-pentanoic acid, t-butyl ester

Dissolve 85% potassium hydroxide (3.96g, 60mmol) in absolute ethanol (60mL). Add 5-(3-bromopropyl)-hydantoin (see Example 9) (6.63g, 30mmol) and a solution of ethyl carbazate (6.3g, 60mmol) in absolute ethanol (40mL). Reflux for 3 hours, cool and filter to remove potassium bromide. Evaporate the solvent *in vacuo*, dissolve the residue in water (30mL), neutralize with dilute hydrochloric acid, cool and collect 5-[3-(carbethoxyaminoxy)-propyl]-hydantoin.

Mix 5-[3-(carbethoxyhydrazino)-propyl]-hydantoin (2.44g, 10mmol), barium hydroxide octahydrate (18.15g, 10mmol) and water (55mL). Reflux for 12 hours, remove the white solid by filtration and extract the filter cake with boiling water (25mL) and finally wash with hot water (25mL). Combine the filtrate and washings, treat with ammonium carbonate (5.7g) and heat with stirring. Filter off the barium carbonate, wash the filter cake with hot water and evaporate the filtrate and washings *in vacuo* to give 2-amino-5-hydrazino-pentanoic acid.

Dissolve 2-amino-5-hydrazino-pentanoic acid (14.7g, 0.1mol) in 1N sodium hydroxide (200mL, 0.2mol). Add a solution of CuSO₄ · 5H₂O (12.5g, 0.05mol) in water (50mL). Stir the mixture until solution is complete. Treat with benzyl chloroformate (17.1g, 0.1mol) and stir at room temperature until reaction is complete. Suction filter, wash the residue with 1:3.5 methanol-water and dry at 60° C to give the copper complex. Suspend the copper complex in water, treat with excess hydrogen sulfide, heat to boiling, then cool to room temperature. Mix with 1N sodium hydroxide and filter. Stir the filtrate with a slight excess of 1N hydrochloric acid and filter. Wash the residue with water and dry to give N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid.

Suspend N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid (84.4g, 0.3mol) in t-butyl acetate

(250mL) and cool to 10° C. Add p-toluenesulfonic acid (57g, 0.3mol) and add, by dropwise addition, concentrated sulfuric acid (80mL). Stir at 10° C until the reaction is complete, basify to pH 8 by adding a suspension of sodium bicarbonate in water. Extract with ethyl acetate, dry (MgSO₄), and evaporate to give N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester.

- 5 Dissolve N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester (3.37g, 10mmol) in 50/50 dioxane/water (25mL) and buffer to PH 10 with 1N sodium hydroxide. Add, by dropwise addition, an ether solution of t-butyl azidoformate (1.58g, 11mmol) at 10° C. Allow to warm to room temperature and buffer occasionally to retain pH 10. Acidify with a sodium citrate/citric acid buffer to pH 5, extract with ether (3X), dry (MgSO₄) and blow to a residue with a stream of nitrogen to give N-tert-butyloxycarbonyl-N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester.

- 10 Mix N-tert-butyloxycarbonyl-N⁷-benzyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester (2.18g, 5.0mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure. Filter and evaporate the filtrate *in vacuo* to give N-t-butyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester.

- 15 Dissolve N-t-butyloxycarbonyl-2-amino-5-hydrazino-pentanoic acid, t-butyl ester (2.91g, 10mmol) in methylene dichloride (30mL), place under a nitrogen atmosphere and cool to 0° C. Add triphosgene (2.81g, 10mmol) and allow to stir at room temperature for 2 hours to give the crude title compound.

20 Step B: N²-t-Butyloxycarbonyl-N⁷-(cyclopropylamino-carbonyl)-2-amino-5-hydrazino-pentanoic acid, t-butyl ester

- Add cyclopropylamine (0.86g, 15mmol) to N-t-butyloxycarbonyl-2-amino-5-[(trichloromethylcarbonate)-hydrazino]-pentanoic acid, t-butyl ester (4.65g, 10mmol) and stir at room temperature for 8 hours. Pour the reaction mixture into water and separate the organic phase. Extract the aqueous phase with ethyl acetate (2X), wash the combined organic phases with saturated sodium chloride and dry (MgSO₄). Evaporate the solvent *in vacuo* and purify by silica gel chromatography to give the title compound.

Step C: N⁷-(Cyclopropylamino-carbonyl)-2-amino-5-hydrazino-pentanoic acid

- 30 Mix N²-t-butyloxycarbonyl-N⁷-(cyclopropylamino-carbonyl)-2-amino-5-hydrazino-pentanoic acid, t-butyl ester (3.86g, 10mmol) and 1N hydrochloric acid (30mL) and stir under a nitrogen atmosphere at room temperature for 4 hours. Pour the reaction mixture into ethyl ether and separate the aqueous phase. Wash the aqueous phase with ethyl ether (2X), the neutralize with 5N sodium hydroxide. Evaporate the water *in vacuo* then purify by ion-exchange chromatography to give the title compound.

- 35 Those compounds of Formula Ia-c in which X is represented by a 2-propyne residue are typically made in the following manner. Initially one of the protected compounds according to Formula Ia'-c' is made in which X is represented by hydrogen. This can be done utilizing the methods taught in Reaction Schemes I-IV. The only modification is that X should be represented by hydrogen in the amino compound of structure (4), the amidino compound of structure (6) and the isocyanate of structure (8).

- 40 Once the appropriate compound of Formula Ia'-c' has been prepared, it is subjected to an N-alkylation reaction with 1-bromo-2-propyne, (ie. a compound of the formula, Br-CH₂-C≡CH). This N-alkylation can be carried out using techniques well known in the art. Approximately equivalent amounts of the reactants are contacted in an aprotic solvent such as toluene, benzene, or dimethylformamide at a temperature ranging from room temperature to reflux. The reaction is allowed to proceed for a period of time ranging from 1 to 16 hours. The desired product may then be recovered by extraction or concentration. It may then be purified by ion exchange chromatography, preparative C₁₈ reverse phase chromatography, or by flash chromatography depending upon the particular protecting group being utilized. This compound may then be subjected to the deprotection and optional functionalizations discussed above in Reactions Schemes I-IV.

- 50 The following example is typical of a compounds of formula Ic, wherein W is CH₂NH₂, X is 2-propyne, and Z is NH. This example is illustrative only and is not intended to limit the scope of the present invention in any way.

Example 14

- 55 Preparation of N⁵-[Imino-(2-propyneamino)methyl]-ornithine

Step A: N²-t-Butyloxycarbonyl-N⁵-[Imino-(2-propyneamino)methyl]-ornithine

Mix N²-t-butyloxycarbonyl-L-arginine HCl (3.10g, 10mmol), anhydrous potassium carbonate (1.38g), dimethylformamide (50mL) and propargyl bromide (1.1mL). Stir at room temperature to 24 hours. Heat to 60 °C for 8 hours, then heat to 90 °C for 16 hours. Acidify, blow to a residue, apply the residue to a Dowex AG50-X8 column and elute with 0.2M NH₄OH and lyophilize to give the title compound.

5

Step B: N⁵-[lmino-(2-propyneamino)methyl]-ornithine

Mix N²-t-butyloxycarbonyl-N⁵-[lmino-(2-propyneamino)methyl]-ornithine (1.44g, 4.6mmol) and 10% palladium/carbon (0.5g) in 95% ethanol (40mL). Hydrogenate at room temperature at atmospheric pressure.

10 Filter and evaporate the filtrate *in vacuo* to give the title compound.

As noted above, the compounds of Formula Ia-c inhibit the biosynthesis of nitric oxide and are therefore useful in the treatment of a number of disease states in which excess levels of nitric oxide play a detrimental role. These include conditions associated with low blood pressure, inflammatory diseases and CNS disorders.

15 As noted above it has been demonstrated that nitric oxide relaxes the smooth muscles of the vasculature, producing a dilatory effect upon these vessels which results in a reduction in blood pressure. Since the compounds of Formula Ia-c inhibit the biosynthesis of nitric oxide, the administration of the compounds of Formula Ia-c will produce a rise in blood pressure and thus can be used to treat conditions associated with low blood pressure. Representative examples of such conditions include shock, endotoxic
20 shock, hypovolemic shock, cardiogenic shock.

In order to exhibit this hypertensive effect it is necessary that the compounds be administered in an amount sufficient to inhibit the biosynthesis of nitric oxide. The dosage range at which these compounds exhibit this hypertensive effect can vary widely depending upon the particular disease being treated, the severity of the patient's disease, the patient, the particular compound being administered, the route of
25 administration, and the presence of other underlying disease states within the patient, etc. Typically the compounds exhibit their hypertensive effects at a dosage range of from about 0.1 mg/kg to 500mg/kg/day. Repetitive daily administration may be desirable and will vary according to the conditions outlined above. Typically, the compounds will be administered from 1-4 times daily.

The ability of these compounds to inhibit the biosynthesis of nitric oxide can be demonstrated by *in*
30 *vitro* assays known in the art. Igengar et al. *Proc. Nat'l. Acad. Sci.*, 84, pages 6369-6373 (Sept. 1987). In this assay macrophages are exposed to bacterial lipopolysaccharides and Interferongamma, which stimulates the macrophages to produce nitric oxide. The compounds of Formula Ia-c will either inhibit or decrease production of nitric oxide by the macrophages.

It is well known in the art that excessive activity by macrophages is implicated in a number of
35 inflammatory diseases such as, for example, rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, cirrhosis of the liver and lungs, sarcoidosis, and granulomatous lesions. In a recent review, Collier et al. stated that it is currently believed that the cytotoxic activity of macrophages is due their ability to produce nitric oxide. *Trends in Pharmacological Sciences*, 10(11), page 123, (1989) Thus the compounds of the instant invention will either inhibit or decrease the amount of nitric oxide which is produced by the
40 macrophages and thus will be useful in the treatment of these disease states associated with excessive activity of macrophages. The compounds will also be useful in preventing transplant rejection by macrophages.

In order to exhibit this beneficial effect in inflammatory diseases, it is necessary that the compounds of Formula Ia-c be administered in a quantity sufficient to inhibit the production of nitric oxide by macro-
45 phages. The dosage range at which these compounds exhibit this effect can vary widely depending upon the particular disease being treated, the severity of the patient's disease, the patient, the particular compound being administered, the route of administration, and the presence of other underlying disease states within the patient, etc. Typically the compounds exhibit their therapeutic effect at a dosage range of from about 0.1 mg/kg/day to about 500 mg/kg/day for any of the diseases or conditions listed above.
50 Repetitive daily administration may be desirable and will vary according to the conditions outlined above.

The ability of these compounds to inhibit the generation of cyclic GMP within the central nervous system can be demonstrated by procedure's known in the art such as Baron et al. *Journal of Pharmacol. and Exp. Therap.*, 250, pages 162-169 (1989). In this test, mice are administered harmaline which produces a rise in cyclic GMP levels with the cerebella of the CNS. The pre-administration of one of the compounds
55 of Formula Ia-c will block the rise in cyclic GMP levels that is typically associated with harmaline administration.

It has been demonstrated that stimulation of the NMDA receptor complex leads to the release of nitric oxide which in turn stimulates guanylate cyclase which in turn produces a rise in cyclic GMP levels. Since

the compounds of Formula Ia-c will inhibit the production of cyclic GMP and thus will negate the physiological effects typically associated with stimulation of the NMDA receptor complex, these compounds will be useful in the treatment of disease states associated with overstimulation of these excitatory neurons. Overstimulation of the NMDA receptor complex has been associated with seizures and thus the compounds of Formula Ia-c exhibit anti-convulsant properties and are useful in the treatment of epilepsy. They are useful in the treatment of grand mal seizures, petit mal seizures, psychomotor seizures, and autonomic seizures.

Overstimulation of the NMDA receptor complex has also been associated with the neurotoxicity associated with ischemic, hypoxic, traumatic, or hypoglycemic conditions. Representative examples of such ischemic, hypoxic, or hypoglycemic conditions include strokes or cerebrovascular accidents, carbon monoxide poisoning, hyperinsulinemia, cardiac arrest, drownings, suffocation, and neonatal anoxic trauma. The compounds should be administered to the patient within 24 hours of the onset of the hypoxic, ischemic, or hypoglycemic condition in order for the compounds to effectively minimize the CNS damage which the patient will experience.

The compounds of Formula Ia-c are also useful in the treatment of neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, senile dementia, glutaric acidemia type I, multi-infarct dementia, and neuronal damage associated with uncontrolled seizures. The administration of these compounds to a patient experiencing such a condition will serve to either prevent the patient from experiencing further neurodegeneration or it will decrease the rate at which the neurodegeneration occurs.

As is apparent to those skilled in the art, the compounds will not correct any CNS damage that has already occurred as the result of either disease or a lack of oxygen or sugar. As used in this application, the term "treat" refers to the ability of the compounds to prevent further damage or delay the rate at which any further damage occurs.

The dosage range at which these compounds will exhibit their effect upon excitatory neurotransmission can vary widely depending upon the particular disease being treated, the severity of the patient's disease, the patient, the particular compound being administered, the route of administration, and the presence of other underlying disease states within the patient, etc. Typically the compounds exhibit their therapeutic effect at a dosage range of from about 0.1 mg/kg/day to about 500 mg/kg/day for any of the diseases or conditions listed above. Repetitive daily administration may be desirable and will vary according to the conditions outlined above.

As used in this application:

a) the term "patient" refers to warm blooded animals such as, for example, guinea pigs, mice, rats, cats, rabbits, dogs, monkeys, chimpanzees, and humans;

b) the term "treat" refers to the ability of the compounds to either relieve, alleviate, or slow the progression of the patient's disease;

c) the term "neurodegeneration" refers to a progressive death and disappearance of a population of nerve cells occurring in a manner characteristic of a particular disease state and leading to brain damage.

d) the term "inflammatory disease" refers to a condition in which activation of leukocytes leads to an impairment of normal physiologic function. Representative examples of such conditions include rheumatoid arthritis, inflammatory bowel disease, sepsis, and adult respiratory distress syndrome.

e) the term "hypotensive condition" refers to a condition in which blood pressure is lowered to a point to which normal physiologic functioning is impaired.

The compounds of the present invention may be administered by a variety of routes. They are effective if administered orally. The compounds may also be administered parenterally (i.e., subcutaneously, intravenously, intramuscularly, intraperitoneally, or intrathecally).

Pharmaceutical compositions can be manufactured utilizing techniques known in the art. Typically an inhibitory amount of the compound will be admixed with a pharmaceutically acceptable carrier.




For oral administration, the compounds can be formulated into solid or liquid preparations such as capsules, pills, tablets, lozenges, melts, powders, suspensions, or emulsions. Solid unit dosage forms can be capsules of the ordinary gelatin type containing, for example, surfactants, lubricants and inert fillers such as lactose, sucrose, and cornstarch or they can be sustained release preparations. In another embodiment, the compounds of Formula Ia-c can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders, such as acacia, cornstarch, or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. Liquid preparations are prepared by dissolving the active ingredient in an aqueous or non-aqueous pharmaceutically acceptable solvent which may also contain suspending agents, sweetening agents, flavoring agents, and preservative agents as are known in the art.

For parenteral administration the compounds may be dissolved in a physiologically acceptable pharmaceutical carrier and administered as either a solution or a suspension. Illustrative of suitable pharmaceutical carriers are water, saline, dextrose solutions, fructose solutions, ethanol, or oils of animal, vegetative, or synthetic origin. The pharmaceutical carrier may also contain preservatives, buffers, etc., as are known in the art. When the compounds are being administered intrathecally, they may also be dissolved in cerebrospinal fluid as is known in the art.

The compounds may also be admixed with any inert carrier and utilized in laboratory assays in order to determine the concentration of the compounds within the serum, urine, etc., of the patient as is known in the art.

Claims

1. Compounds of the formulae Ia, Ib or Ic




in which

- A is represented by $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$ or $-\text{CH}=\text{CH}-$;
 - X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR_2 , in which R_2 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl;
 - R is represented by an amino acid or OM in which M is represented by H, C_{1-6} alkyl, benzyl, phenyl, pivoyl methyl ether,
 - Z is represented by O or NR_1 , in which R_1 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl; and
 - W is represented by a substituent selected from the group consisting of $-\text{CH}_2-\text{NH}-$, $-(\text{CH}_2)_2-\text{NH}-$, $-\text{NH}-\text{NH}-$, $-\text{CH}_2-\text{NH}-\text{NH}-$, $-\text{CH}_2-\text{O}-\text{NH}-$ and $-\text{O}-\text{NH}-$;
- and the pharmaceutically acceptable salts thereof, with the following provisos:
- 1) that when W is $-\text{NH}-\text{NH}-$ or $-(\text{CH}_2)_2-\text{NH}-$ then Z must be represented by O, and
 - 2) when Z is represented by O and X is represented by NR_1 , then W must be $-\text{CH}_2-\text{NH}-$ or $-(\text{CH}_2)_2-\text{NH}-$ and;
 - 3) that when W is represented by $\text{CH}_2-\text{NH}-$, Z is represented NH_2 , and X is NHR_2 , then R_2 is not represented by H.


2. A compound according to claim 1 in which W is -CH₂-NH-, -NH-NH-, or -O-NH-.
3. A compound according to claim 1 in which W is -(CH₂)₂-NH-, -CH₂-NH-NH-, or -CH₂-O-NH-.
4. A process for producing compounds of the formula Ia as defined in claim 1, comprising:
 - a) carrying out a displacement reaction between phosgene (2, Y = Cl) or triphosgene (2, Y = OCCl₃)



and a functionalized amino acid as described by structure (1)



in which A is as defined in claim 1 and Pr is a t-butyloxycarbonyl group, while Pr' is a t-butyl group thereby producing a chloroformate or a trichloromethylurethane as described by structure (3)




in which Pr, Pr' and A are as defined above,

b) subjecting the chloroformate (3, Y = Cl) or the trichloromethylurethane (3, Y = OCCl₃) to an amidation reaction with an amino-derivative as described by structure (4)




in which X is as defined in claim 1, thereby producing the protected compound of formula Ia',



and


c) deprotecting compound Ia' to produce a compound of formula Ia which is
d) optionally functionalized to introduce the substituent R as defined in claim 1 into the molecule.

5. A process for producing compounds of formula Ib in which Z is represented by NR₁, comprising:
 - a) carrying out a displacement reaction between a functionalized amino acid as described by structure (5)




5

in which Pr and Pr' are either hydrogen or protecting groups and an amidino derivative as described by structure (6)



6

in which Alk is represented by a C₁₋₄ alkyl, and R₁ and X are as defined in claim 1, thereby producing the optionally protected compound which has been depicted as Ib',




Ib'

b) subjecting this product to a deprotection reaction, and


c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

6. A process for producing compounds of formula Ic in which Z is represented by NR₁, comprising:
- carrying out a displacement reaction between a functionalized amino acid as described by structure (7)




7

in which W' is -CH₂-NH₂, NH₂-NH-, -CH₂-O-NH₂, -CH₂-NH-NH₂, -(CH₂)₂-NH₂ or -O-NH₂ and in which Pr and Pr' are hydrogen or protecting groups and an amidino derivative as described by structure (6)



6

in which Alk, R₁, and X are as defined in claim 5, thereby producing the compound of formula Ic',




- b) removing the protecting groups, if present, via an acidic hydrolysis, and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

7. A process for producing compounds of formula Ic in which Z is represented by O, comprising:
 a) carrying out an addition reaction between a functionalized amino acid as described by structure (7) as defined in claim 6, and an isocyanate derivative as described by structure (8)




- in which X is as defined in claim 1 wherein Z is O, thereby producing the protected compound of formula Ic'',



- b) deprotecting the compound of formula Ic'', and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

8. A process for producing compounds of formula Ib in which Z is O, comprising:
 a) carrying out the reaction as shown in claim 7, but substituting the following compound (5) for the amino acid of structure (7)






in which Pr and Pr' are as above.

9. Use of a compound according to any of claims 1 to 3 for the preparation of a pharmaceutical composition.
10. Use according to claim 9 wherein the composition is useful for inhibiting the biosynthesis of nitric oxide.
11. Use according to claim 9 wherein the composition is useful for the treatment of hypotensive conditions.
12. Use according to claim 9 wherein the composition is useful for the treatment of inflammatory diseases.
13. Use according to claim 9 wherein the composition is useful for the treatment of epilepsy.
14. Use according to claim 9 wherein the composition is useful for the treatment of neurotoxicity associated with ischemic, hypoxic, traumatic or hypoglycemic conditions.

15. Use according to claim 9 wherein the composition is useful for the treatment of neurodegenerative diseases.
16. A pharmaceutical composition containing a compound according to any of claims 1 to 3 and optionally a pharmaceutically acceptable carrier and/or diluent.
17. The composition according to claim 16 for inhibiting the biosynthesis of nitric oxide.
18. The composition according to claim 16 for the treatment of hypotensive conditions.
19. The composition according to claim 16 for the treatment of inflammatory diseases.
20. The composition according to claim 16 for the treatment of epilepsy.
21. The composition according to claim 16 for the treatment of neurotoxicity associated with ischemic, hypoxic, traumatic or hypoglycemic conditions.
22. The composition according to claim 16 for the treatment of neurodegenerative diseases.

Claims for the following contracting state: GR

1. Compounds of the formulae Ia, Ib or Ic



in which

- A is represented by $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$ or $-\text{CH}=\text{CH}-$;
 X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR_2 , in which R_2 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl;
 R is represented by an amino acid or OM in which M is represented by H, C_{1-6} alkyl, benzyl, phenyl, pivoyl methyl ether,
 Z is represented by O or NR_1 , in which R_1 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl;
 and

W is represented by a substituent selected from the group consisting of $-\text{CH}_2\text{-NH-}$, $-(\text{CH}_2)_2\text{-NH-}$, $-\text{NH-NH-}$, $-\text{CH}_2\text{-NH-NH-}$, $-\text{CH}_2\text{-O-NH-}$ and $-\text{O-NH-}$;

and the pharmaceutically acceptable salts thereof, with the following provisos:

- 1) that when W is $-\text{NH-NH-}$ or $-(\text{CH}_2)_2\text{-NH-}$ then Z must be represented by O, and
- 2) when Z is represented by O and X is represented by NR_1 , then W must be $-\text{CH}_2\text{-NH-}$ or $-(\text{CH}_2)_2\text{-NH-}$ and;
- 3) that when W is represented by $\text{CH}_2\text{-NH-}$, Z is represented NH_2 , and X is NHR_2 , then R_2 is not represented by H.

2. A compound according to claim 1 in which W is $-\text{CH}_2\text{-NH-}$, $-\text{NH-NH-}$, or $-\text{O-NH-}$.


3. A compound according to claim 1 in which W is $-(\text{CH}_2)_2\text{-NH-}$, $-\text{CH}_2\text{-NH-NH-}$, or $-\text{CH}_2\text{-O-NH-}$.

4. A process for producing compounds of the formula Ia as defined in claim 1, comprising:


- a) carrying out a displacement reaction between phosgene (2, $\text{Y} = \text{Cl}$) or triphosgene (2, $\text{Y} = \text{OCCl}_3$)



and a functionalized amino acid as described by structure (1)



in which A is as defined in claim 1 and Pr is a t-butyloxycarbonyl group, while Pr' is a t-butyl group thereby producing a chloroformate or a trichloromethylurethane as described by structure (3)




in which Pr, Pr' and A are as defined above,

- b) subjecting the chloroformate (3, $\text{Y} = \text{Cl}$) or the trichloromethylurethane (3, $\text{Y} = \text{OCCl}_3$) to an amidation reaction with an amino-derivative as described by structure (4)



in which X is as defined in claim 1, thereby producing the protected compound of formula Ia',




and


c) deprotecting compound Ia' to a compound of formula Ia which is

d) optionally functionalized to introduce the substituent R as defined in claim 1 into the molecule.


- 5 5. A process for producing compounds of formula Ib in which Z is represented by NR₁, comprising:
a) carrying out a displacement reaction between a functionalized amino acid as described by structure (5)



15 in which Pr and Pr' are either hydrogen or protecting groups and an amidino derivative as described by structure (6)




25 in which Alk is represented by a C₁₋₄ alkyl, and R₁ and X are as defined in claim 1, thereby producing the optionally protected compound which has been depicted as Ib',



b) subjecting this product to a deprotection reaction, and


c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

- 40 6. A process for producing compounds of formula Ic in which Z is represented by NR₁, comprising:
a) carrying out a displacement reaction between a functionalized amino acid as described by structure (7)




50 in which W' is -CH₂-NH₂, -CH₂-O-NH₂, -CH₂-NH-NH₂, -(CH₂)₂-NH₂ or -O-NH₂ and in which Pr and Pr' are hydrogen or protecting groups and an amidino derivative as described by structure (6)

55




in which Alk, R₁, and X are as defined in claim 5, thereby producing the compound of formula Ic',




- b) removing the protecting groups, if present, via an acidic hydrolysis, and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

7. A process for producing compounds of formula Ic in which Z is represented by O, comprising:
 a) carrying out an addition reaction between a functionalized amino acid as described by structure (7) as defined in claim 6, and an isocyanate derivative as described by structure (8)




in which X is as defined in claim 1 wherein Z is O, thereby producing the protected compound of formula Ic'',



- b) deprotecting the compound of formula Ic'', and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

8. A process for producing compounds of formula Ib in which Z is O, comprising:
 a) carrying out the reaction as shown in claim 7, but substituting the following compound (5) for the amino acid of structure (7)




in which Pr and Pr' are as above.

9. Use of a compound according to any of claims 1 to 3 for the preparation of a pharmaceutical composition.

10. Use according to claim 9 wherein the composition is useful for inhibiting the biosynthesis of nitric oxide.
11. Use according to claim 9 wherein the composition is useful for the treatment of hypotensive conditions.
12. Use according to claim 9 wherein the composition is useful for the treatment of inflammatory diseases.
13. Use according to claim 9 wherein the composition is useful for the treatment of epilepsy.
14. Use according to claim 9 wherein the composition is useful for the treatment of neurotoxicity associated with ischemic, hypoxic, traumatic or hypoglycemic conditions.
15. Use according to claim 9 wherein the composition is useful for the treatment of neurodegenerative diseases.

Claims for the following contracting state: ES

1. A process for producing compounds of the formula Ia,



in which

A is represented by $-(\text{CH}_2)_2-$, $-(\text{CH}_2)_3-$ or $-\text{CH}=\text{CN}-$;


X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR_2 , in which R_2 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl;

R is represented by an amino acid or OM in which M is represented by H, C_{1-6} alkyl, benzyl, phenyl, pivoyl methyl ether, comprising:


a) carrying out a displacement reaction between phosgene (2, $\text{Y} = \text{Cl}$) or triphosgene (2, $\text{Y} = \text{OCCl}_3$)



and a functionalized amino acid as described by structure (1)



in which A is as defined above and Pr is a t-butyloxycarbonyl group, while Pr' is a t-butyl group thereby producing a chloroformate or a trichloromethylurethane as described by structure (3)




in which Pr, Pr' and A are as defined above,

b) subjecting the chloroformate (3, Y = Cl) or the trichloromethylurethane (3, Y = OCCl₃) to an amidation reaction with an amino-derivative as described by structure (4)

NEX

4

in which X is as defined above, thereby producing the protected compound of formula Ia',




and

c) deprotecting compound Ia' to produce a compound of formula Ia which is

d) optionally functionalized to introduce the substituent R as defined above into the molecule.

2. A process for producing compounds of formula Ib




in which

X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR₂' in which R₂ is represented by H, -CF₃, -CH₂CF₃, or C₁₋₆ alkyl;


R is represented by an amino acid or OM in which M is represented by H, C₁₋₆ alkyl, benzyl, phenyl, pivoyl methyl ether,

Z is represented by NR₁, in which R₁ is represented by H, -CF₃, -CH₂CF₃, or C₁₋₆ alkyl, comprising:

a) carrying out a displacement reaction between a functionalized amino acid as described by structure (5)




in which Pr and Pr' are either hydrogen or protecting groups and an amidino derivative as described by structure (6)



in which Alk is represented by a C₁₋₄ alkyl, and R₁ and X are as defined above, thereby producing the optionally protected compound which has been depicted as Ib',

5




b) subjecting this product to a deprotection reaction, and

c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

15

3. A process for producing compounds of formula Ic

20



25

in which

X is represented by cyano, cyclopropyl, 2-propyne, 2,3-butadiene or NHR_2 , in which R_2 is represented by H, $-\text{CF}_3$, $-\text{CH}_2\text{CF}_3$, or C_{1-6} alkyl;

30

R is represented by an amino acid or OM in which M is represented by H, C₁₋₆ alkyl, benzyl, phenyl, pivoyl methyl ether,

Z is represented by NR₁, in which R₁ is represented by H, -CF₃, -CH₂CF₃, or C₁₋₆ alkyl; and

W is represented by a substituent selected from the group consisting of -CH₂-NH-, -(CH₂)₂-NH-, -NH-NH-, -CH₂-NH-NH-, -CH₂-O-NH- and -O-NH-;

35

with the following provisos:

1) that when W is -NH-NH- or $\text{-(CH}_2\text{)}_2\text{-NH-}$ then Z must be represented by O, and


2) when Z is represented by O and X is represented by NR_1 , then W must be $-\text{CH}_2\text{-NH-}$ or $-(\text{CH}_2)_2\text{-NH-}$ and;

40

3) that when W is represented by $\text{CH}_2\text{-NH}$, Z is represented by NH_2 , and X is NHR_2 , then R_2 is not represented by H, comprising:

a) carrying out a displacement reaction between a functionalized amino acid as described by structure (7)


45




50

in which W' is -CH₂-NH₂, -CH₂-O-NH₂, -CH₂-NH-NH₂, -(CH₂)₂-NH₂ or -O-NH₂ and in which Pr and Pr' are hydrogen or protecting groups and an amidino derivative as described by structure (6)

55



in which Alk, R₁, and X are as defined in claim 2, thereby producing the compound of formula Ic',




- b) removing the protecting groups, if present, via an acidic hydrolysis, and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

4. A process for producing compounds of formula Ic as defined in claim 3 in which Z is represented by O instead of NR₁, comprising:
 a) carrying out an addition reaction between a functionalized amino acid as described by structure (7) as defined in claim 3, and an isocyanate derivative as described by structure (8)




in which X is as defined in claim 1 wherein Z is O, thereby producing the protected compound of formula Ic'',



- b) deprotecting the compound of formula Ic'', and
 c) optionally functionalizing to introduce the substituent R as defined in claim 1 into the molecule.

5. A process for producing compounds of formula Ib as defined in claim 2 in which Z is O instead of NR₁, comprising:
 a) carrying out the reaction as shown in claim 4, but substituting the following compound (5) for the amino acid of structure (7)



in which Pr and Pr' are as above.



European
Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 91 10 2796

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int. Cl.5)
A	EP-A-0 277 561 (ENIRICERCHÉ) * page 4, compound no. III * - - -	1	C 07 K 5/06 C 07 C 271/10 C 07 C 271/20
A	EP-A-0 230 037 (ITALFARMACO) * claims 1,10 * - - -	1,16	C 07 C 271/24 C 07 C 275/20 C 07 C 275/26
A	EP-A-0 196 841 (SYNTEX) * column 32, lines 20-30 * - - -	1	C 07 C 279/04 C 07 C 279/16 C 07 C 281/02
A	CHEMICAL ABSTRACTS vol. 84, January 1976, page 20, abstract no. 197d, Columbus, Ohio, US; G.P. WHEELER et al.: "Carbamoylation of amino acids, peptides, and proteins by nitrosoureas" & Cancer Res. 1975, vol. 35, no. 11, part 1, pages 2974-2984 - - -	1	C 07 C 281/06 C 07 C 281/16 // C 07 C 335/06 C 07 C 337/06 A 61 K 31/155 A 61 K 31/17 A 61 K 31/27 A 61 K 31/23
A	CHEMICAL ABSTRACTS vol. 83, no. 25, 22 December 1975, page 421, abstract no. 206526y, Columbus, Ohio, US; A. TURAN et al.: "Removal of the nitro group from nitroarginine and nitroarginine peptides" & Acta Chim. Acad. Sci. Hung. 1975, vol. 85, no. 3, pages 327-332 & formula index 1975, vol. 83, page 539F, column 3, lines 79-81 - - -	1	TECHNICAL FIELDS SEARCHED (Int. Cl.5)
A	TETRAHEDRON LETTERS vol. 29, no. 47, 1988, pages 6183,6184, GB; V. TOLMAN et al.: "Unsaturated amino acids: Synthesis of trans-3,4-didehydro analogues of L-ornithine and L-arginine" * page 6183, compound no. 2 * - - - - -	1	C 07 K 5/06 C 07 C 271/10 C 07 C 271/20 C 07 C 271/24 C 07 C 275/20 C 07 C 275/26 C 07 C 279/04 C 07 C 279/16 C 07 C 281/02 C 07 C 281/06 C 07 C 281/16 C 07 C 335/06 C 07 C 337/06 A 61 K 31/155 A 61 K 31/17 A 61 K 31/27 A 61 K 31/23
The present search report has been drawn up for all claims			
Place of search		Date of completion of search	Examiner
Berlin		10 June 91	KAPTEYN H G
CATEGORY OF CITED DOCUMENTS X: particularly relevant if taken alone Y: particularly relevant if combined with another document of the same category A: technological background O: non-written disclosure P: intermediate document T: theory or principle underlying the invention E: earlier patent document, but published on, or after the filing date D: document cited in the application L: document cited for other reasons &: member of the same patent family, corresponding document			